Evidence map›Paper›PMID 34885719›Full record

ArticleMolecules (Basel, Switzerland)2021

Design, Synthesis and Tumour-Selective Toxicity of Novel 1-[3-{3,5-Bis(benzylidene)-4-oxo-1-piperidino}-3-oxopropyl]-4-piperidone Oximes and Related Quaternary Ammonium Salts.

Praveen K Roayapalley, Jonathan R Dimmock, Lisett Contreras, Karol S Balderrama, Renato J Aguilera, Hiroshi Sakagami, Shigeru Amano, Rajendra K Sharma, Umashankar Das

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Chemical constituents in the rhizome of Curcuma longa and the pharmacological importance of curcumin hybrids.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Recent advances in piperidones as privileged scaffolds for drug discovery and development.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Praveen K RoayapalleyDrug Discovery and Development Research Cluster, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Jonathan R DimmockDrug Discovery and Development Research Cluster, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Lisett ContrerasDepartment of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Karol S BalderramaDepartment of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Renato J AguileraDepartment of Biological Sciences and Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Hiroshi SakagamiResearch Institute of Odontology, Meikai University, Sakado, Saitama 350-0283, Japan.ORCID 0000-0001-8001-2121
Shigeru AmanoResearch Institute of Odontology, Meikai University, Sakado, Saitama 350-0283, Japan.
Rajendra K SharmaDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Umashankar DasDrug Discovery and Development Research Cluster, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
University of Saskatchewan · CAThe University of Texas at El Paso · USMeikai University · JP

Funding

UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Yong Qin · 2019 to 2026
$35.1M
RISE Scholars Program at UTEPR25GM069621 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2004 to 2021
$11.2M
Characterization of novel compounds with anti-lymphoma activitySC3GM103713 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2013 to 2016
$453k
Japan Society for the Promotion of Science 16K11519National Institute for Minority Health and Health Disparities (NIMHD) the Border Biomedical Research Center at UREP 5U54MD007592NIGMS NIH HHS 1SC3GM103713NIGMS RISE training grant R25 GM069621-16UTEP Building Scholars grants RL5GM118969, TL4GM118971 and UL1GM118970
6 · The paper itself

Abstract

A novel series of 1-[3-{3,5-bis(benzylidene)-4-oxo-1-piperidino}-3-oxopropyl]-4-piperidone oximes

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationColonic NeoplasmsHumansOximesQuantitative Structure-Activity RelationshipQuaternary Ammonium CompoundsAntineoplastic AgentsOximesQuaternary Ammonium Compoundsconjugated unsaturated ketonescytotoxinsmitochondrial membrane potentialoximesQSARquaternary ammonium salts

Identifiers

PMID34885719
PMCPMC8659243
OpenAlexW3215940754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.